Saturday 17 October 2026
Export PHAR’s income statement to Excel — free account
Pharming Group N.V. Sponsored ADR
PHAR Healthcare Biotechnology
Pharming Group N.V. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 26.6% from fiscal 2024. In the quarter to June 2026, revenue fell 3.22%, EPS fell 57.1%, free cash flow fell 183.9% and total debt rose 1.55%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
9.36
0.27
−2.80%
Follow PHAR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
1,450.00 | 441.75 | 87.58 | 92.60 |
P/S ratio |
2.73 | 3.24 | 3.35 | 2.02 | |
P/FCF ratio |
18.76 | 22.56 | 22.24 | 21.56 | |
P/Operating CF |
30.87 | 113.67 | 634.83 | (76.70) | |
P/B ratio |
3.74 | 4.39 | 4.61 | 2.74 | |
Price to Tangible BV |
7.62 | 8.60 | 8.98 | 5.20 | |
EV/Sales |
2.54 | 3.02 | 3.16 | 1.86 | |
EV/EBITDA |
21.93 | 30.63 | 29.38 | 22.26 | |
EV/Operating CF |
17.25 | 20.75 | 20.68 | 19.42 | |
EV/FCF |
17.46 | 21.04 | 20.95 | 19.80 | |
Quick Ratio |
2.39 | 2.03 | 2.06 | 2.31 | |
Current Ratio |
3.16 | 2.59 | 2.63 | 3.01 | |
Net Debt/EBITDA |
(3.70) | (8.62) | 40.19 | (13.93) | |
Debt/Assets |
20.76% | 19.61% | 20.18% | 20.91% | |
Debt/Equity |
0.37 | 0.35 | 0.37 | 0.36 | |
Asset Turnover |
0.81 | 0.84 | 0.83 | 0.80 | |
Operating CF/Net income |
4.27 | 1.96 | (0.37) | (6.04) | |
Capex/Depreciation |
(0.03) | (0.08) | (0.08) | (0.03) | |
Research and Development Expense of Revenue |
24.05% | 30.15% | 35.28% | 35.81% | |
Selling, General and Administrative Expense of Revenue |
52.52% | 48.15% | 62.85% | 48.23% | |
Intangible Assets out of Total Assets |
0.28 | 0.27 | 0.27 | 0.27 | |
Share Based Compensation of Revenue |
3.29% | 4.23% | 4.45% | 3.71% | |
Graham Net Nets |
0.07 | 0.06 | 0.06 | 0.11 | |
Graham Number |
0.93 | 1.90 | 3.93 | 4.14 | |
Earnings Yield |
0.07% | 0.23% | 1.14% | 1.08% | |
Free Cash Flow Yield |
5.33% | 4.43% | 4.50% | 4.64% | |
Revenue per Share |
1.43 | 1.55 | 0.97 | 1.69 | |
Operating CF per Share |
0.47 | 0.16 | 0.03 | (0.18) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.47 | 0.15 | 0.02 | (0.18) | |
Cash per Share |
2.45 | 2.61 | 2.29 | 2.97 | |
Shareholders Equity per Share |
3.88 | 4.02 | 3.61 | 5.07 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.88 | 4.02 | 3.61 | 5.07 | |
Free Cash Flow |
31.96 | 10.44 | 1.71 | (9.74) | |
Working Capital |
189.69 | 183.68 | 183.17 | 187.44 | |
Capital Expenditures |
(0.07) | (0.27) | (0.24) | (0.08) | |
Net Current Asset Value |
68.46 | 76.61 | 75.11 | 83.20 | |
EV/EBIT |
35.06 | 43.93 | 41.72 | 36.83 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
37.67 | 47.10 | 44.30 | 40.10 | |
| Other line items | |||||
Average Receivables |
45.90 | 54.76 | 53.76 | 55.15 | |
Average Payables |
75.43 | 86.26 | 86.14 | 80.35 | |
Average Inventory |
64.68 | 60.31 | 61.96 | 64.57 | |
Average Assets |
449.65 | 449.97 | 446.27 | 457.12 | |
Average Common Equity |
245.22 | 249.08 | 242.13 | 255.02 |
Columns are period end dates